title: Low-dose total body irradiation and G-CSF without hematopoietic stem cell support in the treatment of relapsed or refractory acute myelogenous leukemia (AML), or AML in second or subsequent remission.
abstract: OBJECTIVE
  Patients with relapsed acute myelogenous leukemia (AML), who are not eligible for bone marrow transplantation, have a poor prognosis when treated with chemotherapy alone. Total body irradiation (TBI) is an effective modality against AML when used in doses of 1000-1400 cGy with hematopoietic stem cell support. We undertook a phase I study of TBI with granulocyte-colony-stimulating factor (G-CSF) support, without stem cell support in patients with AML either in relapse or second or subsequent remission.
  
  
  METHODS
  Patients with relapsed AML, or AML in second or subsequent remission were treated in a phase I study of TBI followed by G-CSF. The first dose level was 200 cGy. After the initial cohort of patients it was clear that patients with overt leukemia did not benefit from this treatment, and subsequent patients were required to be in remission at the time of TBI.
  
  
  RESULTS
  Eleven patients were treated, 4 in overt relapse, and 7 in remission. 200 cGy was used in all, and dose escalation was not possible due to prolonged thrombocytopenia in all patients but one. Neutrophil recovery was adequate in those patients who remained in remission after TBI. Patients with overt leukemia had transient reduction in blast counts, but rapid recurrence of their leukemia. Patients treated in remission had short remissions, with the exception of one patient who is in remission 32 months after treatment.
  
  
  CONCLUSIONS
  There is some antileukemic effect of TBI even at 200 cGy, though this dose appears to be too low to help a significant number of patients. If TBI is to be escalated without stem cell support, then a thrombopoietic agent will need to be used.
authors.affiliation: Division of Hematology-Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: L N
authors.initials: LN
authors.lastname: Shulman
authors.forename: N J
authors.initials: NJ
authors.lastname: Tarbell
authors.forename: E
authors.initials: E
authors.lastname: Storen
authors.forename: K
authors.initials: K
authors.lastname: Marcus
authors.forename: P M
authors.initials: PM
authors.lastname: Mauch
mesh_terms: D000368:Aged; D001752:Blast Crisis; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011879:Radiotherapy Dosage; D012008:Recurrence; D012074:Remission Induction; D013921:Thrombocytopenia / Q000209:etiology; D014916:Whole-Body Irradiation
chemical_list: D016179:Granulocyte Colony-Stimulating Factor